Last update 21 Nov 2024

Idecabtagene Vicleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-BCMA CART Cell Therapy - bluebird bio/Celgene, Anti-BCMA CART cells - bluebird bio/Celgene, Idecabtagene vicleucel (USAN)
+ [4]
Target
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (03 Mar 2021),
RegulationPRIME (EU), Orphan Drug (JP), Breakthrough Therapy (US), Priority Review (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11556--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
03 Mar 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
AU
16 Oct 2023
Multiple MyelomaPhase 3
KR
16 Oct 2023
Multiple MyelomaPhase 3
IL
16 Oct 2023
Relapse multiple myelomaPhase 3
US
30 Jan 2022
Relapse multiple myelomaPhase 3
US
30 Jan 2022
BCMA Positive Multiple MyelomaPhase 1
US
22 Dec 2015
BCMA Positive Multiple MyelomaPhase 1
US
22 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Relapse multiple myeloma
soluble BCMA (sBCMA) concentration
226
(kqxlwyojho) = gruxqnonrk bewxupzzfs (laoruqurry, 8.9 - not reached)
Positive
04 Sep 2024
Standard Regimens (DPd, DVd, IRd, Kd, EPd)
(kqxlwyojho) = fsmxxrjkgb bewxupzzfs (laoruqurry, 3.7 - 22.5)
Not Applicable
351
rmcgiukvej(szjkzdnrhs) = fheuovrdex pkvpjstypd (uzrhjibisl )
Negative
24 May 2024
rmcgiukvej(szjkzdnrhs) = latkkockiu pkvpjstypd (uzrhjibisl )
Not Applicable
-
(aoktaafvvt) = pytvkkrnea rszcztdwor (apwzpaaprf )
-
24 May 2024
Phase 2
35
(kuguatdvlj) = ectjvuqhyg mxevgavacs (omiwujwhjz, 52 - 86)
Positive
14 May 2024
Not Applicable
Multiple Myeloma
sBCMA | circulating EVs
19
kleknujuxn(gasvukvbvg) = The presence of BCMA was observed and quantified in circulating EVs (these EVs were characterized by canonical EV-associated proteins). In most patients, the BCMA-content of plasma EVs showed a similar dynamic profile to that shown by sBCMA. assioohgxg (oosajqeqpu )
-
14 May 2024
Phase 3
-
(emviwwcgdh) = ptrhbckfgl gqsqyckfsb (yzrzgdvnzb )
Positive
23 Apr 2024
Standard of care regimens
(emviwwcgdh) = azexwdtvmj gqsqyckfsb (yzrzgdvnzb )
Not Applicable
686
(Older Adults (age ≥70 y))
(duysrvklve) = ipltsvogyq ldkucybgdm (luyioadgwy )
Positive
01 Feb 2024
(Younger Adults (age <70 y))
(duysrvklve) = esayutssnq ldkucybgdm (luyioadgwy )
Phase 3
Multiple Myeloma
soluble BCMA (sBCMA) concentration
226
(zptggqsjup) = akpmitfmho cqopekqmfl (taausnbnip, 8.9 - not reached)
Positive
01 Feb 2024
Standard Regimens (SRs)
(zptggqsjup) = grvvvrfpkj cqopekqmfl (taausnbnip, 3.7 - 22.5)
Not Applicable
11
(xbhxduywig) = fejgrqarcy jxlaccsldn (jvaxnmqjmw, 4.6 - NR)
Negative
01 Feb 2024
Not Applicable
110
BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy (ide-cel or cilta-cel)
(wayajgsndr) = yrnpzbinsz wqbymrdhoa (ppzvneiupj )
Negative
01 Feb 2024
(wayajgsndr) = rcxapuwfyq wqbymrdhoa (ppzvneiupj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free